MYND Life Sciences Inc. Share Price

Equities

MYND

CA62857B1094

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 14:51:57 05/06/2024 BST 5-day change 1st Jan Change
0.04 CAD +100.00% Intraday chart for MYND Life Sciences Inc. 0.00% 0.00%

Financials

Sales 2022 - Sales 2023 - Capitalization 717K 981K 56.64M
Net income 2022 -3M -4.1M -237M Net income 2023 -1M -1.37M -78.97M EV / Sales 2022 -
Net Debt 2022 2.59 3.54 204.2 Net Debt 2023 3 4.1 236.88 EV / Sales 2023 -
P/E ratio 2022
-1.05 x
P/E ratio 2023
-0.47 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 40.17%
More Fundamentals * Assessed data
Dynamic Chart
MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive Director CI
Mynd Announces Transition of Dr. Lyle Oberg, E.C.A. to Executive Chairman from the Role of CEO CI
Mynd Announces Transition of Dr. Lyle Oberg, E.C.A. from the Role of CEO to Executive Chairman CI
MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive Officer CI
MYND Life Sciences Inc. Appoints John Campbell as President CI
MYND Life Sciences Inc. entered into a non-binding letter of intent to acquire Cava Healthcare Inc. CI
MYND Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
MYND Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023 CI
MYND Life Sciences Inc. Auditor Raises 'Going Concern' Doubt CI
MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2022 CI
MYND Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022 CI
VMYND Lifesciencs Inc. cancelled the acquisition of Tidal Psychedelics. CI
More news
1 day+100.00%
Current month+100.00%
1 month+33.33%
3 months+33.33%
More quotes
1 month
0.02
Extreme 0.02
0.04
Current year
0.01
Extreme 0.01
0.04
1 year
0.01
Extreme 0.005
0.10
3 years
0.01
Extreme 0.005
1.90
5 years
0.01
Extreme 0.005
2.50
10 years
0.01
Extreme 0.005
2.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 25/11/20
Founder 63 05/07/18
Founder 65 05/07/18
Members of the board TitleAgeSince
Founder 65 05/07/18
Founder 63 05/07/18
Chief Executive Officer 53 25/11/20
More insiders
MYND Life Sciences Inc. is a Canada-based medical biotech drug research and development company. The Company is focused on neuro-pharmaceutical drug development, diagnostics and vaccines. It is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio) pharmaceutical companies by molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property. The Company is engaged in collaborative research with the Michael Smith Laboratories at the University of British Columbia.
More about the company